{
    "clinical_study": {
        "@rank": "25322", 
        "brief_summary": {
            "textblock": "The purpose of this ascending dose group study is to assess the safety, tolerability, and\n      effects of multiple dose levels of INS37217 and placebo followed by five days twice daily\n      treatment with maximum tolerated dose administered by inhalation via the Pari LC Star\n      nebulizer in adult and pediatric patients with cystic fibrosis"
        }, 
        "brief_title": "A Study in Adult and Pediatric Patients With Cystic Fibrosis", 
        "completion_date": {
            "#text": "August 2002", 
            "@type": "Actual"
        }, 
        "condition": "Cystic Fibrosis", 
        "condition_browse": {
            "mesh_term": [
                "Cystic Fibrosis", 
                "Fibrosis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  FEV1 40-70% (adults)\n\n          -  FEV1 >/=50% (pediatrics)\n\n          -  oxygen saturation >90%\n\n          -  clinically stable\n\n          -  willing to stay overnight\n\n        Exclusion Criteria:\n\n          -  abnormal renal or liver function\n\n          -  receiving corticosteroids exceeding 10mg/day or 20 mg every other day\n\n          -  received intravenous or aerosolized antibiotics 1 week prior to dosing"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "5 Years"
        }, 
        "enrollment": {
            "#text": "63", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 29, 2002", 
        "id_info": {
            "nct_id": "NCT00034515", 
            "org_study_id": "08-102"
        }, 
        "intervention": {
            "intervention_name": "denufosol tetrasodium (INS37217) Inhalation Solution", 
            "intervention_type": "Drug"
        }, 
        "lastchanged_date": "March 14, 2014", 
        "official_title": "Ph 1b/2a Study to Assess Levels of INS37217 and Placebo Treatment With Maximum Tolerated Dose Administered by Inhalation Via the Pari LC Star Nebulizer in Adult and Pediatric CF Patients", 
        "overall_official": {
            "last_name": "Amy Schaberg, BSN", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "August 2002", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "assess safety and tolerability"
        }, 
        "removed_countries": {
            "country": "United States"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00034515"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "results_reference": {
            "PMID": "15704203", 
            "citation": "Deterding R, Retsch-Bogart G, Milgram L, Gibson R, Daines C, Zeitlin PL, Milla C, Marshall B, Lavange L, Engels J, Mathews D, Gorden J, Schaberg A, Williams J, Ramsey B; Cystic Fibrosis Foundation Therapeutics Development Network. Safety and tolerability of denufosol tetrasodium inhalation solution, a novel P2Y2 receptor agonist: results of a phase 1/phase 2 multicenter study in mild to moderate cystic fibrosis. Pediatr Pulmonol. 2005 Apr;39(4):339-48."
        }, 
        "secondary_outcome": {
            "measure": "assess effects of INS37217 on sputum weight and symptoms"
        }, 
        "source": "Merck Sharp & Dohme Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2001", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }, 
    "geocoordinates": {}
}